TABLE 3.
Pituitary Height (mm) in 3 Patient Subsets
| Hypopituitary Patients
|
Anti-CTLA-4 Treatment: No Autoimmunity
|
Anti-CTLA-4 Treatment: Autoimmunity
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient | Pre-Tx (mm) | Max (mm) | Change (%) | Pre-Tx (mm) | Maximum (mm) | Change (%) | Pre-Tx (mm) | Maximum (mm) | Change (%) |
| 1 | 5.3 | 10.7 | 102 | 5.3 | 5.9 | 11 | 5.6 | 4.8 | −14 |
| 2 | 3.4 | 11.5 | 238 | 6 | 5.6 | −7 | 7.7 | 7.7 | 0 |
| 3 | 4.8 | 7.7 | 60 | 7.8 | 8.7 | 12 | 6.4 | 7.9 | 23 |
| 4 | 0 | 0 | 0 | 5.4 | 3.1 | −43 | 6 | 6.5 | 8 |
| 5 | 6 | 10.2 | 70 | 6.6 | 7.6 | 15 | 7 | 7 | 0 |
| 6 | 5.5 | 11.5 | 109 | 6.6 | 5.5 | −17 | − | − | − |
| 7 | 4.5 | 11.8 | 162 | − | − | − | − | − | − |
| 8 | 4.1 | 11.4 | 178 | − | − | − | − | − | − |
Pre-Tx measurement taken before anti-CTLA-4 antibody treatment.
Max measurement taken at the maximal height of the pituitary gland while on treatment.
Pre-Tx indicates pretreatment.